Lilly to present new clinical data for Verzenio and multiple novel pipeline programs at the 2025 European Society for Medical Oncology Annual Meeting
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lilly's Kisunla receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
U.S. FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Lilly's Mounjaro , a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
Blackrock Announces Arrangements to Address Mailing of Meeting Materials Resulting from the Canada Post Strike
